secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0000929638-23-003423
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene appoints Ryan Daws as CFO with $440K salary, 232K stock option grant
---------------------------------------------------------------------------

- Ryan Daws appointed CFO effective Nov 27, 2023; base salary $440,000, target bonus 40%.
- One-time sign-on bonus of $143,500 payable Jan 2024; must repay if leaves within 1 year or terminated for cause.
- Granted option for 232,000 common shares at fair market value on Nov 30, 2023; 25% vests on 1st anniversary, monthly thereafter.
- Severance on termination without cause or for good reason: 12 months base salary, COBRA, prorated bonus, and partial equity acceleration.
- On change in control termination: full equity acceleration plus 12 months base and target bonus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000092963823003423/0000929638-23-003423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000092963823003423/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-23-003423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer